Actively Recruiting
Evaluating Remibrutinib for Severe Chronic Pruritus of Unknown Origin in Adults A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
180
Participants Needed
17
Research Sites
16 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating remibrutinib in adult participants with severe chronic pruritus of unknown origin CPUO, a condition causing persistent severe itching without a known cause. This phase 3, global, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of remibrutinib for this condition. Participants will undergo up to 60 weeks of study divided into four periods. After a screening period of up to 4 weeks, participants enter a 24-week double-blind phase receiving either remibrutinib or placebo. Then, a 28-week open-label phase follows, where all participants receive remibrutinib. Lastly, there is a 4-week treatment-free safety follow-up period. Throughout the study, participants will be regularly assessed for itch severity using the Worst Itch Numerical Rating Scale and Patient Global Impression of Severity. Researchers will monitor sleep disturbance related to itching, record adverse events, and evaluate treatment tolerability. The entire participation can last up to 60 weeks, including treatment and follow-up phases.
CONDITIONS
Brief Title
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here